CRISPR-Cas systems, revolutionizing genetic engineering, represent a prokaryotic adaptive immune system repurposed for precise genome editing.  Initially discovered in bacteria as a defense mechanism against bacteriophages, the mechanism involves clustered regularly interspaced short palindromic repeats (CRISPR) arrays transcribed into guide RNAs (gRNAs). These gRNAs, alongside Cas proteins (most commonly Cas9), form a complex that targets and cleaves specific DNA sequences complementary to the gRNA. This targeted cleavage induces a double-strand break, triggering the cell's DNA repair mechanisms, either non-homologous end joining (NHEJ), resulting in insertions or deletions, or homology-directed repair (HDR), facilitating precise gene modification via a provided DNA template.  While naturally occurring systems have been harnessed, significant advancements have involved engineering improved Cas variants with altered specificity and activity, enabling more efficient and precise genome editing.  The relative simplicity, efficiency, and programmability of CRISPR-Cas technology have propelled its widespread adoption across diverse research fields, from basic biological research to therapeutic applications, showcasing its transformative potential in genetic engineering.